BG Medicine gets new CEO; sees sales double
This article was originally published in Clinica
Executive Summary
Cardiovascular diagnostic specialist BG Medicine has appointed Paul Sohmer president and CEO, replacing Eric Bouvier who is stepping down after being in charge for just over a year. The company did not say why Dr Bouvier, who took up the role in January 2012, was leaving, but noted he had helped transform BG Medicine from an R&D-focused firm to a commercial organization. New CEO Dr Sohmer most recently led diagnostic company Viracor-IBT Laboratories; before this, he held the same position with implantable device developer Orthocon; and has also headed up Cylex, Pathway Diagnostics and Neuromedical Systems (before its acquisition by TriPath Imaging – after this he was TriPath’s chairman, president and CEO, before its acquisition by Becton Dickinson, www.clinica.co.uk, 5 January 2007). This latest change at BG Medicine follows the replacement of Michael Rogers by Charles Abdalian as vice-president and CFO last year (www.clinica.co.uk, 23 October 2012).